Last reviewed · How we verify
Investigational H7N1 vaccine GSK2789869A
Investigational H7N1 vaccine GSK2789869A is a Biologic drug developed by GlaxoSmithKline. It is currently in Phase 2 development.
At a glance
| Generic name | Investigational H7N1 vaccine GSK2789869A |
|---|---|
| Sponsor | GlaxoSmithKline |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Immunogenicity and Safety Study of Different Formulations of GlaxoSmithKline (GSK) Biologicals H7N1 Influenza Vaccine Administered to Adults 65 Years of Age and Older (PHASE2)
- Immunogenicity and Safety Study of Different Formulations of GlaxoSmithKline (GSK) Biologicals H7N1 Influenza Vaccine Administered to Adults 21 to 64 Years of Age (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Investigational H7N1 vaccine GSK2789869A CI brief — competitive landscape report
- Investigational H7N1 vaccine GSK2789869A updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI
Frequently asked questions about Investigational H7N1 vaccine GSK2789869A
What is Investigational H7N1 vaccine GSK2789869A?
Investigational H7N1 vaccine GSK2789869A is a Biologic drug developed by GlaxoSmithKline.
Who makes Investigational H7N1 vaccine GSK2789869A?
Investigational H7N1 vaccine GSK2789869A is developed by GlaxoSmithKline (see full GlaxoSmithKline pipeline at /company/gsk).
What development phase is Investigational H7N1 vaccine GSK2789869A in?
Investigational H7N1 vaccine GSK2789869A is in Phase 2.